비만 치료 시장 보고서(2026년)

The anti-obesity drugs refer to medications that are used to reduce or regulate a patient's weight. These drugs interfere with one of the body's basic functions, weight control, by affecting either appetite or calorie absorption. Dieting (a healthy diet and caloric restriction) and exercise continue to be the primary therapeutic approaches for people who are overweight or obese.

The main classes of drugs in anti-obesity are peripherally acting anti-obesity drugs and centrally acting anti-obesity drugs. Anti-obesity medications with a peripheral effect help people lose weight without affecting the brain or reducing appetite. They block pancreatic lipase and inhibit fat breakdown in the gastrointestinal tract, thereby reducing fat absorption through the intestine. The different types of drugs include prescription drugs (Rx) and OTC drugs and involve various medications such as monotherapies and polytherapy.

Tariffs have raised the cost of imported APIs used in anti-obesity drug manufacturing and formulation activities. These impacts are most significant in North America and Europe, where many metabolic drug manufacturers depend on global API supply networks. Increasing tariff-related input costs have placed pressure on production economics and pricing strategies for weight management therapies. This has affected procurement planning and market access decisions among pharmaceutical companies. However, tariffs are also encouraging domestic manufacturing of metabolic drugs, localized API production, and stronger regional pharmaceutical supply chains over the long term.

The antiobesity market research report is one of a series of new reports from The Business Research Company that provides antiobesity market statistics, including antiobesity industry global market size, regional shares, competitors with a antiobesity market share, detailed antiobesity market segments, market trends and opportunities, and any further data you may need to thrive in the antiobesity industry. This antiobesity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiobesity market size has grown strongly in recent years. It will grow from $4.13 billion in 2025 to $4.53 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing global obesity rates, limited effectiveness of lifestyle-only interventions, availability of appetite suppressants, rising burden of metabolic disorders, physician-led weight management.

The antiobesity market size is expected to see strong growth in the next few years. It will grow to $6.61 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes and obesity, advancements in hormone-based drugs, expansion of reimbursement coverage, growing obesity awareness, and increasing demand for sustainable weight loss solutions. Major trends in the forecast period include the rapid adoption of GLP-1-based therapies, growing preference for prescription weight loss drugs, increasing use of combination anti-obesity therapies, greater focus on long-term weight management, and expanding access to obesity treatment.

The increasing prevalence of obesity is expected to drive the growth of the anti-obesity drugs market going forward. Obesity is a chronic metabolic condition characterized by excessive accumulation of body fat, which increases the risk of serious health complications, including diabetes, cardiovascular diseases, osteoarthritis, and certain cancers. The increasing prevalence of obesity is attributed to the growing consumption of ultra-processed foods that are high in sugars, unhealthy fats, and refined carbohydrates, along with sedentary lifestyles that limit physical activity. This rise in obesity prevalence is increasing the demand for effective anti-obesity medical interventions, supportive weight management therapies, and long-term treatment solutions to reduce associated health risks and enhance patient outcomes. For instance, in March 2024, according to the World Obesity Federation, a UK-based organization focused on obesity research and advocacy, 79% of adults with overweight and obesity and 88% of children with overweight and obesity are projected to be living in low- and middle-income countries by 2035. Therefore, the increasing prevalence of obesity is driving the growth of the anti-obesity drugs market.

Major companies operating in the antiobesity market are emphasizing product innovation and formulation, including dual glucose-dependent insulinotropic peptide receptor agonists, to deliver more effective weight loss, enhanced metabolic outcomes, and improved tolerability. These therapies utilize synergistic effects on appetite suppression, insulin sensitivity, and energy expenditure to achieve greater efficacy compared with earlier-generation GLP-1-only treatments. For instance, in December 2024, Eli Lilly, a US-based pharmaceutical company, received FDA approval for Zepbound (tirzepatide), making it the first and only prescription dual GIP/GLP-1 agonist approved for chronic weight management. Tirzepatide has demonstrated strong weight-loss efficacy, with participants in phase 3 trials achieving substantial reductions in body weight. With this new indication, Zepbound is expected to strengthen Lilly's leadership in the precision obesity therapy space, addressing the growing demand for long-acting, high-efficacy treatments.

In August 2023, Eli Lilly, a US-based pharmaceutical company, acquired Versanis Bio for an undisclosed amount. Through this acquisition, Eli Lilly aims to strengthen its antiobesity drug portfolio by incorporating Versanis Bio's innovative therapies targeting metabolic and weight-management pathways, supporting the development of next-generation treatments for obesity and related metabolic disorders. Versanis Bio is a US-based biotechnology company that specializes in developing novel therapeutics for obesity and metabolic diseases, with a strong track record in preclinical and early-stage clinical research.

Major companies operating in the antiobesity market are Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd.

North America was the largest region in the anti-obesity market in 2025. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antiobesity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-obesity market consists of sales of liraglutide, semaglutide, naltrexone-bupropion, and orlistat. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antiobesity Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses antiobesity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antiobesity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antiobesity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Peripherally Acting Anti-Obesity Drugs; Centrally Acting Anti-Obesity Drugs
• 2) By Type: Prescription Drugs (Rx); OTC Drugs
• 3) By Medication: Monotherapies; Polytherapies
• Subsegments:
• 1) By Peripherally Acting Anti-Obesity Drugs: Orlistat; Lorcaserin
• 2) By Centrally Acting Anti-Obesity Drugs: Phentermine; Topiramate; Naltrexone-Bupropion Combination; Liraglutide
• Companies Mentioned: Takeda Pharmaceutical Company Limited; Eisai Co. Ltd.; Novo Nordisk A/S; Zafgen Inc.; Rhythm Pharmaceuticals Inc.; Zydus Cadila; Norgine B.V.; Vivus Inc.; Arena Pharmaceuticals Inc.; Orexigen Therapeutics Inc.; Eli Lilly and Company; Amgen Inc.; AstraZeneca PLC; Viking Therapeutics Inc.; Structure Therapeutics Inc.; Gelesis Inc.; Sanofi S.A.; F. Hoffmann-La Roche Ltd; Teva Pharmaceutical Industries Limited; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.; Lupin Ltd.; Torrent Pharmaceuticals Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Antiobesity Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Antiobesity Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Antiobesity Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Antiobesity Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rapid Adoption Of Glp-1 Based Therapies
  • 4.2.2 Growing Preference For Prescription Weight Loss Drugs
  • 4.2.3 Increasing Use Of Combination Antiobesity Therapies
  • 4.2.4 Rising Focus On Long-Term Weight Management
  • 4.2.5 Expansion Of Obesity Treatment Access

5. Antiobesity Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Weight Management Clinics
• 5.3 Endocrinology Clinics
• 5.4 Retail Pharmacies
• 5.5 Specialty Care Centers

6. Antiobesity Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Antiobesity Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Antiobesity PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Antiobesity Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Antiobesity Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Antiobesity Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Antiobesity Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Antiobesity Market Segmentation

• 9.1. Global Antiobesity Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs
• 9.2. Global Antiobesity Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prescription Drugs (Rx), OTC Drugs
• 9.3. Global Antiobesity Market, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monotherapies, Polytherapies
• 9.4. Global Antiobesity Market, Sub-Segmentation Of Peripherally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Orlistat, Lorcaserin
• 9.5. Global Antiobesity Market, Sub-Segmentation Of Centrally Acting Anti-Obesity Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Phentermine, Topiramate, Naltrexone-Bupropion Combination, Liraglutide

10. Antiobesity Market Regional And Country Analysis

• 10.1. Global Antiobesity Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Antiobesity Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Antiobesity Market

• 11.1. Asia-Pacific Antiobesity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Antiobesity Market

• 12.1. China Antiobesity Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Antiobesity Market

• 13.1. India Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Antiobesity Market

• 14.1. Japan Antiobesity Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Antiobesity Market

• 15.1. Australia Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Antiobesity Market

• 16.1. Indonesia Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Antiobesity Market

• 17.1. South Korea Antiobesity Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Antiobesity Market

• 18.1. Taiwan Antiobesity Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Antiobesity Market

• 19.1. South East Asia Antiobesity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Antiobesity Market

• 20.1. Western Europe Antiobesity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Antiobesity Market

• 21.1. UK Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Antiobesity Market

• 22.1. Germany Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Antiobesity Market

• 23.1. France Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Antiobesity Market

• 24.1. Italy Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Antiobesity Market

• 25.1. Spain Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Antiobesity Market

• 26.1. Eastern Europe Antiobesity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Antiobesity Market

• 27.1. Russia Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Antiobesity Market

• 28.1. North America Antiobesity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Antiobesity Market

• 29.1. USA Antiobesity Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Antiobesity Market

• 30.1. Canada Antiobesity Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Antiobesity Market

• 31.1. South America Antiobesity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Antiobesity Market

• 32.1. Brazil Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Antiobesity Market

• 33.1. Middle East Antiobesity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Antiobesity Market

• 34.1. Africa Antiobesity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Antiobesity Market, Segmentation By Drug Class, Segmentation By Type, Segmentation By Medication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Antiobesity Market Regulatory and Investment Landscape

36. Antiobesity Market Competitive Landscape And Company Profiles

• 36.1. Antiobesity Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Antiobesity Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Antiobesity Market Company Profiles
  • 36.3.1. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Zafgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Rhythm Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Antiobesity Market Other Major And Innovative Companies

• Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd.

38. Global Antiobesity Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Antiobesity Market

40. Antiobesity Market High Potential Countries, Segments and Strategies

• 40.1 Antiobesity Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Antiobesity Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Antiobesity Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer